Page 93 - 202002

[6] HENRY RR ， MURRAY AV ， [11] XU L,LI Y,LANG J,ET AL.

MARMOLEJO MH ， et al. Dapagliflozin, EFFECTS OF SODIUM-GLUCOSE CO-
metformin XR, or both: initial TRANSPORTER 2 (SGLT2) INHIBITION
pharmacotherapy for type 2 diabetes, a ON RENAL FUNCTION AND

randomised controlled trial[J].Int JClin ALBUMINURIA IN PATIENTS WITH
Pract,2012,66:446-456. TYPE 2 DIABETES: A SYSTEMATIC
REVIEW AND META-ANALYSIS[J].
[7] BOLINDER J,LJUNGGREN
PeerJ,2017,5:e3405.
Ö,KULLBERG J,et al. Effects of dapa⁃
gliflozin on body weight，total fat mass， [12] TERAMI N,OGAWA
and regional adipose tis⁃ D,TACHIBANA H,et al. Long-term

suedistributioninpatientswithtype treatment with the sodium glucose
2diabetesmellituswithinad-equate cotransporter 2 inhibitor,dapagliflozin ，
glycemic control on metformin[J].J Clin ameliorates glucose homeostasis and

Endocrinol Metab, 2012, 97:1020-1031. diabetic nephropathy in db/db mice[J].
PLoSOne,2014,9:e100777.
[8] Thomas A. Zelniker, MD, MSC,
Eugene Braunwald. Clinical Benefit of [13] KOHLER S,SALSALI A,HANTEL

Cardiorenal Effects of Sodium-Glucose S,et al. Safety and Tolerability of
Cotransporter 2 Inhibitors JACC State-of- Empagliflozin in Patients with Type 2
the-Art Review[J].J AM COLL Diabetes[J]. Clin Ther,2016,38(6):1299-

CARDIOL,2020,75(4):435-447. 1313.

[9] KATO ET,SILVERMAN 作者简介
MG,MOSENZON O.et al.Effect of 朱 岚，杭州市中医院内分泌科副主

Dapagliflozin on Heart Failure and 任医师，2006年毕业于浙江大学医学院，
Mortality in Type 2 Diabetes Mellitus[J]. 获临床医学硕士学位，主持参加多项省市
Circulation,2019,139:2528-2536.
级科研项目，发表论文多篇，2016年赴英

[10] SATIRAPOJ B. Sodium⁃glucose 国皇家格罗斯特医院进修。
cotransporter 2 inhibitors with reno-
protectiveeffects[J]. KidneyDis,2017,

3:24-32.

c͆ͅḤḤc